Moneycontrol PRO
HomeNewsBusinessCompaniesPfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt

Pfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt

Bourla said that Pfizer will be able to produce 3 billion vaccines by the end of 2021, and 4 billion vaccines in 2022.

June 22, 2021 / 18:59 IST

Pfizer CEO Albert Bourla on June 22 said the US-based drug maker is final stages to sign an agreement with Indian government to supply COVID-19 vaccines.

"We are discussing with India govt, we are in final stages of finalising agreement," Bourla said at the 15th annual BioPharma & Healthcare Summit, USA-India Chamber of Commerce (USAIC)

"We need to get approval of this vaccine in India. We are in a good way to get approval. Then we have to have a sign an agreement that will allow us to send doses," Bourla said.

Bourla said that Pfizer will be able to produce 3 billion vaccines by the end of 2021, and 4 billion vaccines in 2022.

Bourla said Pfizer has specific plans to meet the demand of COVID-19 vaccines for lower and middle income countries (LMIC) including India.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

As part of the plan, LMIC countries will receive at least two billion doses of Pfizer's COVID-19 vaccines, and at least 1 billion of this will be this year alone.

Bourla said Pfizer recently concluded a deal with the US government, wherein US government purchases 500 million of COVID-19 doses at below the cost of production, and give to LMIC countries at free of cost.

"They're going to be 7 billions within two years.. beginning of next year.. the world will have a lot of vaccines available for all," Bourla said.

Viswanath Pilla
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 22, 2021 06:59 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
CloseOutskill Genai